
Protagonist Therapeutics, Inc.: shareholders and insiders
Price
$124.02
November 19, 2026Market cap $7.9B
What Ploutos Investor adds for Protagonist Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 9 fiscal years, from 2017
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- Earnings per share here are the last twelve months' earnings over today's shares, so they agree with the P/E. The number of shares changed a lot during the year, so they differ from the earnings per share the company filed, which use the year's average number of shares.
Insiders and their shares
Purchases and sales by officers and directors from Nov 20, 2025 to Nov 17, 2026, from their own Form 4 filings.
Bought on the market
–
nobody
Sold on the market
$88M
7 people
From Nov 20, 2025 to Nov 20, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan59%
- The rest41%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 20, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·no buys·sold $80M by 7 people
- 2025: no buys, no sales
- 2026: no buys, sold $80M by 7 people
- Nov 16, 2026Arturo Md MolinaChief Medical OfficerKind
- Sep 30, 2026Asif AliChief Financial OfficerKind10b5-1
- Sep 30, 2026Asif AliChief Financial OfficerKind10b5-1
- Sep 30, 2026Asif AliChief Financial OfficerKind10b5-1
- Sep 30, 2026Asif AliChief Financial OfficerKind10b5-1
- Sep 30, 2026Asif AliChief Financial OfficerKind10b5-1
- Sep 30, 2026Asif AliChief Financial OfficerKind10b5-1
- Sep 10, 2026Dinesh V Ph D PatelPresident and CEOKind10b5-1
- Sep 10, 2026Dinesh V Ph D PatelPresident and CEOKind10b5-1
- Sep 9, 2026Dinesh V Ph D PatelPresident and CEOKind10b5-1
- Sep 9, 2026Dinesh V Ph D PatelPresident and CEOKind10b5-1
- Sep 8, 2026Dinesh V Ph D PatelPresident and CEOKind10b5-1
- Sep 8, 2026Dinesh V Ph D PatelPresident and CEOKind10b5-1
- Sep 3, 2026Dinesh V Ph D PatelPresident and CEOKind
- Aug 11, 2026Dinesh V Ph D PatelPresident and CEOKind10b5-1
- Aug 11, 2026Dinesh V Ph D PatelPresident and CEOKind10b5-1
- Aug 10, 2026Dinesh V Ph D PatelPresident and CEOKind10b5-1
- Aug 10, 2026Dinesh V Ph D PatelPresident and CEOKind10b5-1
- Jun 23, 2026William D. WaddillDirectorKind10b5-1
- Jun 23, 2026William D. WaddillDirectorKind10b5-1
- Jun 10, 2026William D. WaddillDirectorKind10b5-1
- Jun 10, 2026William D. WaddillDirectorKind10b5-1
- Jun 10, 2026William D. WaddillDirectorKind10b5-1
- May 29, 2026William D. WaddillDirectorKind10b5-1
- May 29, 2026William D. WaddillDirectorKind10b5-1
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 16, 2026 | Arturo Md MolinaChief Medical Officer | 2,718 | $124.65 | $338.8K | Form 4 | |
| Sep 30, 2026 | Asif AliChief Financial Officer | 10b5-1 | 9,229 | $38.98 | $359.7K | Form 4 |
| Sep 30, 2026 | Asif AliChief Financial Officer | 10b5-1 | 28.4K | $23.42 | $666.0K | Form 4 |
| Sep 30, 2026 | Asif AliChief Financial Officer | 10b5-1 | 15.7K | $19.19 | $300.3K | Form 4 |
| Sep 30, 2026 | Asif AliChief Financial Officer | 10b5-1 | 5,312 | $12.17 | $64.6K | Form 4 |
| Sep 30, 2026 | Asif AliChief Financial Officer | 10b5-1 | 12.6K | $141.77 | $1.8M | Form 4 |
| Sep 30, 2026 | Asif AliChief Financial Officer | 10b5-1 | 46.0K | $141.78 | $6.5M | Form 4 |
| Sep 10, 2026 | Dinesh V Ph D PatelPresident and CEO | 10b5-1 | 7,278 | $21.58 | $157.1K | Form 4 |
| Sep 10, 2026 | Dinesh V Ph D PatelPresident and CEO | 10b5-1 | 7,278 | $144.10 | $1.0M | Form 4 |
| Sep 9, 2026 | Dinesh V Ph D PatelPresident and CEO | 10b5-1 | 63.5K | $21.58 | $1.4M | Form 4 |
| Sep 9, 2026 | Dinesh V Ph D PatelPresident and CEO | 10b5-1 | 63.5K | $146.18 | $9.3M | Form 4 |
| Sep 8, 2026 | Dinesh V Ph D PatelPresident and CEO | 10b5-1 | 54.2K | $21.58 | $1.2M | Form 4 |
| Sep 8, 2026 | Dinesh V Ph D PatelPresident and CEO | 10b5-1 | 54.2K | $145.87 | $7.9M | Form 4 |
| Sep 3, 2026 | Dinesh V Ph D PatelPresident and CEO | 510 | – | – | Form 4 | |
| Aug 11, 2026 | Dinesh V Ph D PatelPresident and CEO | 10b5-1 | 34.2K | $21.58 | $738.9K | Form 4 |
| Aug 11, 2026 | Dinesh V Ph D PatelPresident and CEO | 10b5-1 | 34.2K | $148.52 | $5.1M | Form 4 |
| Aug 10, 2026 | Dinesh V Ph D PatelPresident and CEO | 10b5-1 | 65.8K | $21.58 | $1.4M | Form 4 |
| Aug 10, 2026 | Dinesh V Ph D PatelPresident and CEO | 10b5-1 | 65.8K | $149.11 | $9.8M | Form 4 |
| Jun 23, 2026 | William D. WaddillDirector | 10b5-1 | 9,000 | $16.54 | $148.9K | Form 4 |
| Jun 23, 2026 | William D. WaddillDirector | 10b5-1 | 9,000 | $117.94 | $1.1M | Form 4 |
| Jun 10, 2026 | William D. WaddillDirector | 10b5-1 | 3,000 | $11.80 | $35.4K | Form 4 |
| Jun 10, 2026 | William D. WaddillDirector | 10b5-1 | 6,000 | $16.54 | $99.2K | Form 4 |
| Jun 10, 2026 | William D. WaddillDirector | 10b5-1 | 9,000 | $107.68 | $969.1K | Form 4 |
| May 29, 2026 | William D. WaddillDirector | 10b5-1 | 9,000 | $11.80 | $106.2K | Form 4 |
| May 29, 2026 | William D. WaddillDirector | 10b5-1 | 9,000 | $99.64 | $896.8K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 1, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by PTGX's officers and directors from 2016 up to November 19, 2025, 10 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 5 more, back to 2016
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- BlackRock, Inc.Share of class15.2%
- Farallon Capital Management, L.L.C.with 28 more personsShare of class9.99%
- RTW Investments, LPwith 1 more personShare of class8.10%
- Vanguard Portfolio ManagementShare of class5.53%
- State StreetShare of class5.20%
- Wellington Management Group LLPwith 2 more personsShare of class5.10%
- Vanguard Capital ManagementShare of class5.09%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| BlackRock, Inc. | 15.2% | 9.83M | Oct 27, 20264 filings since Feb 5, 2025 | 13G/A | |
| Farallon Capital Management, L.L.C.with 28 more persons | 9.99% | 6.43M | Aug 13, 20263 filings since Feb 10, 2025 | 13G/A | |
| RTW Investments, LPwith 1 more person | 8.10% | 5.06M | Feb 17, 2026 | 13G/A | |
| Vanguard Portfolio Management | 5.53% | 3.53M | Apr 29, 2026 | 13G | |
| State Street | 5.20% | 3.32M | Aug 7, 20264 filings since May 13, 2025 | 13G | |
| Wellington Management Group LLPwith 2 more persons | 5.10% | 3.17M | Feb 10, 2026 | 13G | |
| Vanguard Capital Management | 5.09% | 3.25M | Apr 30, 2026 | 13G |
Fell to 5% or less (3)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Duquesne (Druckenmiller)In the quarter
- Renaissance TechnologiesIn the quarter
- Bridgewater (Dalio)In the quarter
- D.E. ShawIn the quarter
- AQR CapitalIn the quarter+91%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Duquesne (Druckenmiller) | – | – | 0.59% | |
| Renaissance Technologies | 77.0K | $11M | 0.01% | |
| Bridgewater (Dalio) | – | – | 0.00% | |
| D.E. Shaw | 6,453 | $900.0K | 0.00% | |
| AQR Capital | 25.0K | +91% | $3.5M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 16.1% of its shares outstanding were held short, +10.2% since the report before.
- Shares held short
- 10.30M
- 16.1%
- Since the report before9.35M on Sep 30, 2026
- +10.2%
- 12.0
- 856.4K
- More days to cover thanof 4,578 US-listed companies with enough volume
- 95%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 3.94M
- Nov 15, 2023: Shares held short 3.65M
- Nov 30, 2023: Shares held short 3.64M
- Dec 15, 2023: Shares held short 3.98M
- Dec 29, 2023: Shares held short 2.35M
- Jan 12, 2024: Shares held short 2.55M
- Jan 31, 2024: Shares held short 2.61M
- Feb 15, 2024: Shares held short 2.78M
- Feb 29, 2024: Shares held short 2.94M
- Mar 15, 2024: Shares held short 3.42M
- Mar 28, 2024: Shares held short 3.44M
- Apr 15, 2024: Shares held short 3.52M
- Apr 30, 2024: Shares held short 3.73M
- May 15, 2024: Shares held short 3.47M
- May 31, 2024: Shares held short 3.38M
- Jun 14, 2024: Shares held short 3.12M
- Jun 28, 2024: Shares held short 2.04M
- Jul 15, 2024: Shares held short 3.26M
- Jul 31, 2024: Shares held short 2.90M
- Aug 15, 2024: Shares held short 3.10M
- Aug 30, 2024: Shares held short 3.28M
- Sep 13, 2024: Shares held short 3.23M
- Sep 30, 2024: Shares held short 3.52M
- Oct 15, 2024: Shares held short 3.00M
- Oct 31, 2024: Shares held short 3.28M
- Nov 15, 2024: Shares held short 3.30M
- Nov 29, 2024: Shares held short 3.40M
- Dec 13, 2024: Shares held short 3.61M
- Dec 31, 2024: Shares held short 3.80M
- Jan 15, 2025: Shares held short 3.67M
- Jan 31, 2025: Shares held short 3.79M
- Feb 14, 2025: Shares held short 4.22M
- Feb 28, 2025: Shares held short 4.87M
- Mar 14, 2025: Shares held short 5.13M
- Mar 31, 2025: Shares held short 4.71M
- Apr 15, 2025: Shares held short 5.57M
- Apr 30, 2025: Shares held short 6.12M
- May 15, 2025: Shares held short 5.29M
- May 30, 2025: Shares held short 5.21M
- Jun 13, 2025: Shares held short 5.91M
- Jun 30, 2025: Shares held short 6.73M
- Jul 15, 2025: Shares held short 6.18M
- Jul 31, 2025: Shares held short 5.76M
- Aug 15, 2025: Shares held short 6.31M
- Aug 29, 2025: Shares held short 6.85M
- Sep 15, 2025: Shares held short 6.66M
- Sep 30, 2025: Shares held short 6.64M
- Oct 15, 2025: Shares held short 6.31M
- Oct 31, 2025: Shares held short 5.47M
- Nov 14, 2025: Shares held short 5.58M
- Nov 28, 2025: Shares held short 5.88M
- Dec 15, 2025: Shares held short 6.54M
- Dec 31, 2025: Shares held short 7.29M
- Jan 15, 2026: Shares held short 8.30M
- Jan 30, 2026: Shares held short 8.13M
- Feb 13, 2026: Shares held short 8.44M
- Feb 27, 2026: Shares held short 8.19M
- Mar 13, 2026: Shares held short 8.06M
- Mar 31, 2026: Shares held short 8.63M
- Apr 15, 2026: Shares held short 8.40M
- Apr 30, 2026: Shares held short 7.54M
- May 15, 2026: Shares held short 7.29M
- May 29, 2026: Shares held short 7.41M
- Jun 15, 2026: Shares held short 7.73M
- Jun 30, 2026: Shares held short 7.69M
- Jul 15, 2026: Shares held short 8.29M
- Jul 31, 2026: Shares held short 7.54M
- Aug 14, 2026: Shares held short 7.79M
- Aug 31, 2026: Shares held short 7.71M
- Sep 15, 2026: Shares held short 8.14M
- Sep 30, 2026: Shares held short 9.35M
- Oct 15, 2026: Shares held short 10.30M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading62.2% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 62.2% of the shares in the reported trades were short sales, against 66.9% in the 14 before.
- Last 14 sessionsNov 2, 2026 – Nov 19, 2026
- 62.2%
- The 14 beforeOct 13, 2026 – Oct 30, 2026
- 66.9%
- Change
- -4.7 pts
- Short sales a dayon average, of 198.7K shares
- 123.6K
- More than atof 3,666 US-listed companies, same days
- 87%
- Median of alleight in ten from 34.5% to 63.8%
- 50.4%
- Short sales
- Oct 13, 2026: Short sales 75.3%
- Oct 14, 2026: Short sales 78.3%
- Oct 15, 2026: Short sales 75.7%
- Oct 16, 2026: Short sales 74.7%
- Oct 19, 2026: Short sales 64.6%
- Oct 20, 2026: Short sales 37.1%
- Oct 21, 2026: Short sales 63.9%
- Oct 22, 2026: Short sales 77.2%
- Oct 23, 2026: Short sales 64.5%
- Oct 26, 2026: Short sales 77.8%
- Oct 27, 2026: Short sales 55.4%
- Oct 28, 2026: Short sales 62%
- Oct 29, 2026: Short sales 62.4%
- Oct 30, 2026: Short sales 57.8%
- Nov 2, 2026: Short sales 57.5%
- Nov 3, 2026: Short sales 62.4%
- Nov 4, 2026: Short sales 56.3%
- Nov 5, 2026: Short sales 70.5%
- Nov 6, 2026: Short sales 72.9%
- Nov 9, 2026: Short sales 56.5%
- Nov 10, 2026: Short sales 58.8%
- Nov 11, 2026: Short sales 59.8%
- Nov 12, 2026: Short sales 67.8%
- Nov 13, 2026: Short sales 27.1%
- Nov 16, 2026: Short sales 68.6%
- Nov 17, 2026: Short sales 74.6%
- Nov 18, 2026: Short sales 61.6%
- Nov 19, 2026: Short sales 75.8%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Dinesh V Ph D PatelPresident and CEODirectly523.0K
- Suneel GuptaChief Development OfficerDirectly267.0K
- Arturo Md MolinaChief Medical OfficerDirectly81.4K
- Harold E SelickDirectorDirectly60.8K
- Asif AliChief Financial OfficerDirectly59.0K
- Bryan GiraudoDirectorDirectly12.7K
- William D. WaddillDirectorDirectly7,825
- Lewis T WilliamsDirectorDirectly7,825
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Dinesh V Ph D PatelPresident and CEO | 523.0K | – | Sep 10, 2026 | Form 4 |
| Suneel GuptaChief Development Officer | 267.0K | – | Nov 26, 2024 | Form 4 |
| Arturo Md MolinaChief Medical Officer | 81.4K | – | Nov 16, 2026 | Form 4 |
| Harold E SelickDirector | 60.8K | – | Mar 26, 2026 | Form 4 |
| Asif AliChief Financial Officer | 59.0K | – | Sep 30, 2026 | Form 4 |
| Bryan GiraudoDirector | 12.7K | – | May 8, 2026 | Form 4 |
| William D. WaddillDirector | 7,825 | – | Jun 23, 2026 | Form 4 |
| Lewis T WilliamsDirector | 7,825 | – | Feb 17, 2026 | Form 4 |
A lower bound: it counts only the 8 officers and directors with a market trade since Nov 21, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- XBIState Street(R) SPDR(R) S&P(R) Biotech ETFWeight in the fund1.07%
- LABUDirexion Daily S&P Biotech Bull 3X SharesWeight in the fund0.88%
- IJTiShares S&P Small-Cap 600 Growth ETFWeight in the fund0.81%
- IBBiShares Biotechnology ETFWeight in the fund0.58%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.45%
- SPSMState Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETFWeight in the fund0.40%
- IJRiShares Core S&P Small-Cap ETFWeight in the fund0.40%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.29%
- IWMiShares Russell 2000 ETFWeight in the fund0.23%
- VBKVanguard Small-Cap Growth Index FundWeight in the fund0.22%
25 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 275
- Q4 2025: Managers 318
- Q1 2026: Managers 322
- Q2 2026: Managers 345
Institutional investors by quarter
The fund managers holding PTGX, quarter by quarter, from Q3 2016 to Q2 2025, 36 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 345 managers held 75.86M shares, worth $9.3B. During the quarter 64 opened a position, 41 closed one, 133 added and 86 trimmed.
The largest holders, Q2 2026
- BlackRockIn the quarter+5.4%
- Farallon Capital ManagementIn the quarter
- Rtw InvestmentsIn the quarter
- Vanguard Portfolio ManagementIn the quarter+4.3%
- Wellington Management GroupIn the quarter-5.1%
- UBS GroupIn the quarter-34%
- State StreetIn the quarter+6.6%
- Vanguard Capital ManagementIn the quarter+1.7%
- Johnson & JohnsonIn the quarter
- InvescoIn the quarter+8.1%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| BlackRock | 10.31M | +5.4% | $1.3B |
| Farallon Capital Management | 6.35M | $778M | |
| Rtw Investments | 5.06M | $620M | |
| Vanguard Portfolio Management | 3.63M | +4.3% | $445M |
| Wellington Management Group | 3.42M | -5.1% | $419M |
| UBS Group | 3.40M | -34% | $417M |
| State Street | 3.32M | +6.6% | $407M |
| Vanguard Capital Management | 2.85M | +1.7% | $350M |
| Johnson & Johnson | 2.45M | $300M | |
| Invesco | 2.34M | +8.1% | $287M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Protagonist Therapeutics's filings show?
Who buys and sells is one part of Protagonist Therapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have PTGX's insiders bought or sold?
From Jun 1, 2026 to Nov 17, 2026 Protagonist Therapeutics's insiders bought 0 and sold $45M of shares on the market. 99% of the sales were under set 10b5-1 plans.
Which well-known managers hold PTGX?
5 of the managers we track held the shares on Sep 30, 2026. The largest position was Renaissance Technologies's, worth $11M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.